Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
J Cell Biochem. 2013 Oct;114(10):2356-62. doi: 10.1002/jcb.24583.
We sought to determine whether the estrogen receptor-related receptor gamma (mEsrrg) regulated the Osteopontin (Opn) promoter through the same AP1/CAAT box element that we have previously described for mEsrra. In HeLa cells mEsrrg used an additional site present in the 5'UTR, while in ROS17/2.8 cells the AP1/CAAT site was not used, but a completely novel site surrounding the transcription start site was used. We also find that in ROS17/2.8 cells mEsrra repressed, while mEsrrg activated the Opn promoter. None of the sites identified conform to established Esrr response elements (ERREs). Additionally, the two reported mEsrrg protein isoforms showed differences in their activation potential. Mutations in the activation function 2 (AF2) of mEsrra, predicted to abolish activation, surprisingly turned mEsrra into a better activator. In contrast, similar AF2 mutations in Esrrg2 abolished its ability to activate the Opn promoter. Mutation of the DNA binding domain of mEsrra/g2 abolished transcriptional activity in HeLa and ROS17/2.8 cells. Our data indicate, first, that the two Esrr isoforms regulate Opn in a cell context-dependent manner. Second, they suggest that although the DNA binding domains of mEsrra and mEsrrg are 93% identical and required for regulation, the receptors bind to distinct Opn promoter elements, suggesting that the two isoforms may co-regulate Opn, and perhaps other genes, without competing for the same site in the promoter. Finally, the results suggest that each isoform interacts differently with co-activators and co-repressors, as highlighted by the AF2 mutation that turns mEsrra into a better activator but abolishes activity of Esrrg2.
我们试图确定雌激素受体相关受体 γ (mEsrrg) 是否通过我们之前描述的 mEsrra 的相同 AP1/CAAT 盒元件来调节骨桥蛋白 (Opn) 启动子。在 HeLa 细胞中,mEsrrg 使用了我们之前描述的 mEsrra 中存在的额外 5'UTR 位点,而在 ROS17/2.8 细胞中,AP1/CAAT 位点未被使用,但使用了完全新颖的围绕转录起始位点的位点。我们还发现,在 ROS17/2.8 细胞中,mEsrra 抑制了 Opn 启动子,而 mEsrrg 激活了 Opn 启动子。鉴定出的所有位点都不符合已建立的 Esrr 反应元件 (ERREs)。此外,两种报道的 mEsrrg 蛋白异构体在其激活潜力方面存在差异。预测会破坏激活的 mEsrra 的激活功能 2 (AF2) 突变,出人意料地将 mEsrra 变成了更好的激活剂。相比之下,Esrrg2 中的类似 AF2 突变使其丧失了激活 Opn 启动子的能力。mEsrra/g2 的 DNA 结合域突变使 HeLa 和 ROS17/2.8 细胞的转录活性丧失。我们的数据表明,首先,这两种 Esrr 异构体以细胞上下文依赖的方式调节 Opn。其次,它们表明,尽管 mEsrra 和 mEsrrg 的 DNA 结合域有 93%的相同,并且需要进行调节,但受体结合到不同的 Opn 启动子元件上,这表明这两种异构体可能共同调节 Opn,并且可能调节其他基因,而不会争夺启动子中的相同位点。最后,结果表明,每个异构体与共激活子和共抑制子的相互作用方式不同,正如 AF2 突变所强调的那样,该突变使 mEsrra 成为更好的激活剂,但使 Esrrg2 的活性丧失。